Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib DDI with Itraconazole and Rifampin
NCT04557397Phase 1Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Sep 2020
- Primary completion
- Oct 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of fruquintinib in colorectal cancer (CRC) (2 arms), sponsored by Hutchison MediPharma (HMP). Primary endpoints: Area Under the Curve from time zero to last quantifiable concentration up to 26 days, Area Under the Curve from time zero to infinity up to 26 days and 1 more. Started Sep 2020; status: completed.
02
Drugs
fruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04557397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04557397.